Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment. On September 29, ...

Pascal Soriot told CNBC that ivonescimab could combine with antibody-drug conjugates to treat tumors that existing ...

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

The biopharmaceutical company plans to expand its Massachusetts workforce by over 50% as the industry faces broader headwinds ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp ...

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...

Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kendall Square will be home to nearly 2,000 world-class researchers and scientists who will accelerate the ...

Oct 2 (Reuters) - AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit's ivonescimab ...